ImmuCell Q4 product sales up 52% to $7.8M; net income $515k vs loss year ago

IMMUCELL CORP /DE/

2024-FY EPS reported -$0.26 revenue$26,493,169

Product sales for Q4 2024 rose 52% to ~$7.8M; full-year sales up 52% to ~$26.5M.
Q4 net income of $515k ($0.06 diluted EPS) vs net loss of $1.14M ($0.15) in Q4 2023.
Gross margin improved to 37% in Q4 2024 from 25% in Q4 2023; EBITDA turned positive at $1.33M.
No contamination events since April 2024; management believes remediation is effective.
Pending FDA clearance for Re-Tain®; NADA submitted Jan 2025 seeking expedited review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.